PADN-PH-LHDHot Line 6Pulmonary Hypertension

Pulmonary Artery Denervation for Pulmonary Hypertension in Left Heart Failure

Pulmonary artery denervation for pulmonary hypertension due to left heart failure

Presenting authorShao-Liang ChenInterventional / Structural Cardiology · Nanjing First Hospital, Nanjing, China

Shao-Liang Chen, MD, PhD, is Vice President of Nanjing First Hospital and Director of the Department of Cardiology at Nanjing Medical University. He is an interventional cardiologist whose research includes the DK Crush technique for coronary bifurcation lesions and pulmonary artery denervation. He has led multicenter trials such as ULTIMATE and IVUS-ACS.

Overview

Pending trial results preclude routine use of pulmonary artery denervation; leaves open its efficacy in pulmonary hypertension due to left heart failure.

Key result

Pulmonary artery denervation for pulmonary hypertension due to left heart failure has pending results from a late-breaking trial at ESC Congress 2026.

Discussion

Expert reaction lands here the moment PADN-PH-LHD reports.

Expert takes

PADN-PH-LHD (also registered as PADN-HF-PH) is a Phase 3, multicenter, randomized controlled trial in China evaluating pulmonary artery denervation (PADN) plus guideline-directed medical therapy versus GDMT alone in 264 patients with pulmonary hypertension due to left heart disease. Full results are scheduled to be presented at ESC 2026 Hot Line 6 by Shao-Liang Chen. There are currently no approved therapies for PH-LHD, making this a high-unmet-need area. Quote supply is very limited as the full trial results have not yet been publicly presented, and most available quotes pertain to adjacent trials (PULSE-LHD, PADN-Columbus) rather than this specific study.

Waleed Al-Darzi

Cardiologist, Henry Ford Health

“This condition affects a large number of patients and remains an area of significant unmet clinical need. We are proud to help lead this important research and look forward to generating evidence that may inform future treatment options for patients.”

Henry Ford Health

Cynthia Chen

Chairlady and President, Pulnovo Medical

“Our focus extends far beyond a single clinical trial; we are building a worldwide clinical foundation focused on generating the evidence needed to determine whether PADN can become a standard of care for cardiopulmonary diseases. By expanding our footprint into the United States, alongside our robust clinical progress in Asia and Europe, we are translating our vision into reality.”

Pulnovo Medical

Key Points

Interventional therapy aims to evaluate whether pulmonary artery denervation reduces pressure loads in pulmonary hypertension secondary to left heart failure.
Late-breaking clinical trial presentation outlines pulmonary artery denervation protocols at ESC Congress 2026, with primary clinical outcomes currently pending.
Clinical evaluation conducted at Nanjing First Hospital investigates catheter-based pulmonary artery denervation, highlighting potential left heart failure care.

Main Result

Absolute Event Rate: 0% vs 0%

AI से पूछें

Bookmark

View Full Paper